NeuroOne Medical Technologies Corp. announced a partnership with the University of Minnesota’s Department of Neurology, Division of Epilepsy, to evaluate its stereoelectroencephalography (sEEG)–based drug delivery platform. The collaboration will begin with large‑animal studies and, if objectives are met, progress to human trials aimed at delivering localized intracerebral therapy for patients with drug‑resistant epilepsy.
Dave Rosa, President and CEO of NeuroOne, said, “The University of Minnesota is at the forefront of next‑generation epilepsy research. As we continue advancing our preclinical drug delivery platform toward commercial readiness, we believe this collaboration will support development of a first‑in‑human study utilizing our technology for intracerebral treatment of epileptic seizures. If successful, this approach could redefine seizure care and establish a new era of precision brain‑directed therapy.”
Dr. Sandipan Pati, Professor and Director of the Division of Epilepsy, added, “Localized intracerebral delivery of therapeutics represents an important emerging direction for improving precision in epilepsy treatment while minimizing systemic side effects. In our clinical practice, we use FDA‑cleared intracranial electrodes for recording brain activity and performing therapeutic interventions such as stimulation and ablation. In parallel, our current research is focused on preclinical studies evaluating the feasibility, safety, and physiological effects of intracerebral drug infusion using minimally invasive intracranial platforms, including ultra‑thin electrode‑based systems designed to reduce tissue disruption.”
Drug‑resistant epilepsy affects roughly 30‑40% of patients worldwide, and localized drug delivery offers a promising way to target seizures while limiting systemic toxicity. The University of Minnesota is a leading epilepsy research center, and its expertise in intracranial electrode technology complements NeuroOne’s sEEG platform, positioning the partnership to accelerate development of a novel therapeutic modality.
On April 14, 2026, NeuroOne completed a 1‑for‑6 reverse stock split effective the following day to regain Nasdaq compliance. The same day, the company reported Q1 Fiscal 2026 earnings: a net loss of $1.4 million, or $‑0.03 per share, beating the consensus estimate of $‑0.04, and revenue of $2.9 million, surpassing the forecast of $2.86 million. The earnings beat reflects disciplined cost management amid a modest revenue increase, while the reverse split underscores the company’s focus on maintaining regulatory compliance and investor confidence.
The collaboration represents a strategic milestone in NeuroOne’s broader drug‑delivery program, which has already secured its first pharmaceutical order. By validating the safety and efficacy of its platform in a leading academic setting, NeuroOne could open a new revenue stream and strengthen its competitive position in the neuromodulation market, potentially accelerating the path to commercialization of its intracerebral drug delivery technology.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.